LabCorp becomes the first firm to obtain emergency use authorisation (EUA) from the FDA for direct-to-consumer multi-analyte COVID-19 test. A kit will be given to the individuals containing all the essential equipments for COVID-19 test. Patients can do a nasal self-test and send the samples back to LabCorp, which will then assess the swab for influenza A and B and SARS-CoV-2 by a thorough examination. LabCorp enables sample collection, at home, without a prescription. The company is capable of processing 30,000 samples a day.
Read More from HealthDive